他汀类药物对急性ST段抬高型心肌梗死患者PCSK9含量的影响

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (743 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To observe the changes in levels of serum proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with acute ST elevation myocardial infarction (STEMI) after statin therapy. Methods: A total of 167 consecutive cases of patients with STEMI were selected. A statin therapy was administered to all patients; in addition, another 50 cases of healthy adults were included as the control group. In STEMI group upon admission, as well as 1 and 4 weeks after statin therapy,and control group, serum PCSK9, blood lipid, troponin I, hsCRP and other indices were determined. Results: PCSK9 level of STEMI group on admission was higher than that of control group (P<0.01), which significantly declined 1 week after statin therapy(P<0.01) and was not significantly different from control group(P=0.135), and that at week 4 of statin therapy was significantly reduced comparing with group upon admission(P<0.01), but was much higher than that of 1 week after statin therapy(P<0.01) and control group(P<0.01). The LDLC level of STEMI group on admission was significantly higher than that of control group (P<0.01), which declined one week after statin therapy(P<0.01) and was not significantly different from control group(P=0.549); and that in STEMI group 4 weeks after statin therapy was further reduced compared with that of 1 week after statin therapy(P<0.01). Conclusion: Serum PCSK9 level in STEMI patients presents dynamic changes within 4 weeks after statin therapy. The declined blood LDLC concentration may facilitate the elevation of PCSK9 level in vivo in a manner of negative feedback, while the elevated PCSK9 in turn will reregulate the plasma LDLC level through negative feedback, and accordingly takes part in the process of cholesterol escape after statin therapy.

Received: 20 October 2016

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2017/V27/I01/64

[1\]中华医学会心血管病学分会，中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南\[J\]. 中华心血管病杂志, 2015, 43(5): 380-393.
\[2\]Seidah NG, Benjannet S, Wickham L, et al.The secretory proprotein convertase neural apoptosisregulated convertase 1(NARC1): liver regeneration and neuronal differentiation\[J\]. Proc Natl Acad Sci USA, 2003, 100(3): 928-933.
\[3\]Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction\[J\]. Eur Heart J, 2012, 33(20): 2551-2567.
\[4\]Chen Z, Zhang X, Ma G, et al. Association study of four variants in KCNQl with type 2 diabetes mellitus and premature coronary arterydisease in a Chinese population \[J\]. Mol Biol Rep, 2010, 37(1): 207-212.
\[5\]Wasko BM, Smits JP, Shull LW, et al. A novel bisphosphonate inhibitor of synthase combined with a statin or a nitrogenousbisphosphonate in vitro\[J\]. J Lipid Res, 2011，52(11): 1957-1964.
\[6\]Tibolla G, Norata GD, Artali R,et al. Proprotein convertase subtilisin /kexin type 9(PCSK9) : from structurefunction relation to therapeutic inhibiton\[J\]. Nutr Metab Cardiovas Dis, 2011, 21(11): 835-843.
\[7\]Cheung BM,Lam KS.Is intensive LDLcholesterol lowering beneficial and safe?\[J\]. Lancet, 2010, 376(9753): 1622-1624.
\[8\]Sasaki J,Otonari T,Sawayama Y,et al.Doubledose pravastatin versus addon ezetimibe with lowdose pravastatineffects on LDL cholesterol,cholesterol absorption,and cholesterol synthesis in Japanese patients with hypercholesterolemia (PEAS study)\[J\]. J Atheroscler Thromb, 2012, 19(5): 485-493.
\[9\]Nicholls SJ, BrandrupWognsen G, Palmer M, et al. Metaanalysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER)\[J\]. Am J Cardiol, 2010, 105(1): 69-76.
\[10\]Yeshurun D, Slobodin G, Keren D, et al. Statin escape phenomenon: Does it really exist?\[J\]. Eur J Intern Med, 2005,16(3):192-194.
\[11\]Ota T, Ishii H, Suzuki S, et al. Impact of the statin escape phenomenon on longterm clinical outcomes in patients with acute myocardial infarction: Subgroup analysis of the Nagoya Acute Myocardial Infarction Study (NAMIS)\[J\]. Atherosclerosis, 2015, 242(1): 155-160.
\[12\]廖玉华，魏晶晶．他汀和PCSK9抑制剂调节LDLC合成与清除代谢的临床荟萃分析\[J\]．临床心血管病杂志，2016,32(6):537-540.
\[13\]Seidah NG,Benjannet S,Wickham L,et al.The secretory proprotein convertase neural apoptosisregulated convertase 1(NARC1):liver regeneration and neuronal differentiation\[J\]. P Natl Acad Sci USA, 2003, 100(3): 928-933.
\[14\]Costet P,Cariou B,Lambent G,et al.Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory elementbinding protein 1c\[J\]. J Biol Chem, 2006, 281(6): 6211-6218.
\[15\]Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia\[J\].Nat Struct Mol Biol, 2007, 14(5): 413-419.
\[16\]Benjannet S, Rhainds D, Hamelin J, et al. The proprotein convertase(PC) PCSK9 is inactivated by fiirin and/ or PC5/6A. Functional consequences of natural mutations and posttranslatinal modifications\[J\]. J Biol Chem, 2006, 281(41): 30561-30572.
\[17\]Leren TP. Mutations in the pcsk9 gene in Norwegian subjects with automal dominant hypercholesterolemia\[J\]. Clin Genet, 2004, 65(5): 419-422.
\[18\]Shioji K, Mannami T, Kokubo Y, et al. Genetic variants in pcsk9 affect the cholesterol level in Japanese\[J\]. J Hum Genet, 2004, 49(2):109-114.
\[19\]Nassoury N,Blasiole DA, Oler AT,et al.The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR\[J\].Traffic,2007,9(8):718-732.